OptimizeRx Co. (NASDAQ:OPRX) CEO Buys $100,200.00 in Stock

OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo purchased 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

OptimizeRx Price Performance

Shares of NASDAQ OPRX opened at $4.78 on Thursday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market cap of $88.05 million, a price-to-earnings ratio of -3.59 and a beta of 1.34. The company’s 50-day moving average price is $5.44 and its 200 day moving average price is $7.89. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $16.65.

Analysts Set New Price Targets

OPRX has been the topic of several recent analyst reports. JMP Securities dropped their target price on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. Royal Bank of Canada cut their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Roth Mkm reissued a “buy” rating and issued a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. William Blair reiterated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Finally, Stifel Nicolaus decreased their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.42.

Institutional Trading of OptimizeRx

Large investors have recently modified their holdings of the business. First Light Asset Management LLC lifted its stake in OptimizeRx by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock valued at $18,270,000 after buying an additional 89,377 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of OptimizeRx by 24.0% in the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after acquiring an additional 119,306 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of OptimizeRx by 12.5% in the second quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock valued at $3,241,000 after acquiring an additional 35,957 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in shares of OptimizeRx by 42.9% during the third quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock valued at $1,868,000 after acquiring an additional 72,672 shares during the last quarter. Finally, Bullseye Asset Management LLC increased its position in OptimizeRx by 55.6% during the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after purchasing an additional 76,458 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.